Plasminogen (Plasmin or PLG or EC 3.4.21.7) – Pipeline Review, H2 2016

Global Markets Direct’s, ‘Plasminogen (Plasmin or PLG or EC 3.4.21.7) – Pipeline Review, H2 2016’, provides in depth analysis on Plasminogen (Plasmin or PLG or EC 3.4.21.7) targeted pipeline therapeutics.

The report provides comprehensive information on the Plasminogen (Plasmin or PLG or EC 3.4.21.7) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Plasminogen (Plasmin or PLG or EC 3.4.21.7) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape for Plasminogen (Plasmin or PLG or EC 3.4.21.7)

The report reviews Plasminogen (Plasmin or PLG or EC 3.4.21.7) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Plasminogen (Plasmin or PLG or EC 3.4.21.7) targeted therapeutics and enlists all their major and minor projects

The report assesses Plasminogen (Plasmin or PLG or EC 3.4.21.7) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Plasminogen (Plasmin or PLG or EC 3.4.21.7) targeted therapeutics

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Plasminogen (Plasmin or PLG or EC 3.4.21.7)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Plasminogen (Plasmin or PLG or EC 3.4.21.7) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies mentioned

Bayer AG

Bharat Biotech International Limited

F. Hoffmann-La Roche Ltd.

Grifols, S.A.

Hyundai Pharmaceutical Co., Ltd.

Kedrion S.p.A.

Nostrum Pharmaceuticals, LLC

Omeros Corporation

ProMetic Life Sciences Inc.

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 5

Introduction 6

Global Markets Direct Report Coverage 6

Plasminogen (Plasmin or PLG or EC

3.4.21.7) Overview 7

Therapeutics Development 8

Plasminogen (Plasmin or PLG or EC

3.4.21.7) - Products under Development by Stage of Development 8

Plasminogen (Plasmin or PLG or EC

3.4.21.7) - Products under Development by Therapy Area 9

Plasminogen (Plasmin or PLG or EC

3.4.21.7) - Products under Development by Indication 10

Plasminogen (Plasmin or PLG or EC

3.4.21.7) - Pipeline Products Glance 11

Late Stage Products 11

Early Stage Products 12

Plasminogen (Plasmin or PLG or EC

3.4.21.7) - Products under Development by Companies 13

Plasminogen (Plasmin or PLG or EC

3.4.21.7) - Therapeutics Assessment 15

Assessment by Monotherapy/Combination Products 15

Assessment by Mechanism of Action 16

Assessment by Route of Administration 18

Assessment by Molecule Type 20

Plasminogen (Plasmin or PLG or EC

3.4.21.7) - Companies Involved in Therapeutics Development 22

Bayer AG 22

Bharat Biotech International Limited 23

F. Hoffmann-La Roche Ltd. 24

Grifols, S.A. 25

Hyundai Pharmaceutical Co., Ltd. 26

Kedrion S.p.A. 27

Nostrum Pharmaceuticals, LLC 28

Omeros Corporation 29

ProMetic Life Sciences Inc. 30

Plasminogen (Plasmin or PLG or EC

3.4.21.7) - Drug Profiles 31

alteplase - Drug Profile 31

Product Description 31

Mechanism Of Action 31

R&D Progress 31

OMS-616 - Drug Profile 33

Product Description 33

Mechanism Of Action 33

R&D Progress 33

plasminogen (human) - Drug Profile 34

Product Description 34

Mechanism Of Action 34

R&D Progress 34

plasminogen (human) - Drug Profile 35

Product Description 35

Mechanism Of Action 35

R&D Progress 35

plasminogen (recombinant) - Drug Profile 37

Product Description 37

Mechanism Of Action 37

R&D Progress 37

Recombinant Prourokinase - Drug Profile 38

Product Description 38

Mechanism Of Action 38

R&D Progress 38

Small Molecule to Inhibit Plasminogen for Rare Bleeding Disorder - Drug Profile 39

Product Description 39

Mechanism Of Action 39

R&D Progress 39

SMRX-11 - Drug Profile 40

Product Description 40

Mechanism Of Action 40

R&D Progress 40

TAL-0500018 - Drug Profile 41

Product Description 41

Mechanism Of Action 41

R&D Progress 41

THR-100 - Drug Profile 43

Product Description 43

Mechanism Of Action 43

R&D Progress 43

TMS-007 - Drug Profile 44

Product Description 44

Mechanism Of Action 44

R&D Progress 44

tranexamic acid - Drug Profile 45

Product Description 45

Mechanism Of Action 45

R&D Progress 45

TTS-01 - Drug Profile 46

Product Description 46

Mechanism Of Action 46

R&D Progress 46

Plasminogen (Plasmin or PLG or EC

3.4.21.7) - Dormant Projects 47

Plasminogen (Plasmin or PLG or EC

3.4.21.7) - Discontinued Products 49

Plasminogen (Plasmin or PLG or EC

3.4.21.7) - Featured News & Press Releases 50

Jun 13, 2016: ProMetic plasminogen granted Fast Track designation by the US FDA 50

May 11, 2016: Positive response in kidney and urinary tract to ProMetic plasminogen treatment in a plasminogen deficient patient under an expanded access protocol in the USA 50

May 10, 2016: Major new global study identifies a safer treatment of acute stroke 51

May 03, 2016: Prometic announces successful treatment of a plasminogen deficient patient under an expanded access (compassionate use) protocol in the USA 52

Feb 18, 2016: Clot-busting therapy reduces mortality in deadliest form of stroke 53

Dec 07, 2015: ProMetic's plasminogen demonstrates rapid therapeutic response in second clinical case 55

Nov 04, 2015: Prometic’S Plasminogen Drug Successfully Used to Treat Plasminogen Deficient Infant in Critical Condition 56

Aug 10, 2015: Prometic Successfully Completes First Dosing In Plasminogen Deficient Patients 56

Aug 04, 2015: European Commission Grants Orphan Drug Designation to ProMetic's Plasma-Derived Plasminogen Drug 57

Jul 23, 2015: MHRA review confirms benefit/risk profile of Alteplase - the only licensed clot buster for acute ischaemic stroke 58

Oct 28, 2014: ProMetic's Plasminogen IND and Clinical Program Cleared by FDA 58

Aug 22, 2014: MHRA To Review Ischemic Stroke Drug 59

Feb 13, 2014: CSIR Developed Clot Specific Streptokinase Enters into Phase-2 Human Clinical Trials 59

Jun 25, 2013: Kedrion Announces Plasminogen clinical study now started on drug for treatment of ligneous conjunctivitis 61

Feb 28, 2013: Mitsubishi Tanabe Pharma And Kyowa Hakko Kirin Receive Japanese Approval For Time-Window Extension Of Thrombolytic Agents GRTPA And Activacin 61

Appendix 62

Methodology 62

Coverage 62

Secondary Research 62

Primary Research 62

Expert Panel Validation 62

Contact Us 62

Disclaimer 63

List of Tables

List of Tables

Number of Products under Development for, H2 2016 8

Number of Products under Development by Therapy Area, H2 2016 9

Number of Products under Development by Indication, H2 2016 10

Comparative Analysis by Late Stage Development, H2 2016 11

Comparative Analysis by Early Stage Products, H2 2016 12

Number of Products under Development by Companies, H2 2016 13

Products under Development by Companies, H2 2016 14

Assessment by Monotherapy/Combination Products, H2 2016 15

Number of Products by Stage and Mechanism of Action, H2 2016 17

Number of Products by Stage and Route of Administration, H2 2016 19

Number of Products by Stage and Molecule Type, H2 2016 21

Pipeline by Bayer AG, H2 2016 22

Pipeline by Bharat Biotech International Limited, H2 2016 23

Pipeline by F. Hoffmann-La Roche Ltd., H2 2016 24

Pipeline by Grifols, S.A., H2 2016 25

Pipeline by Hyundai Pharmaceutical Co., Ltd., H2 2016 26

Pipeline by Kedrion S.p.A., H2 2016 27

Pipeline by Nostrum Pharmaceuticals, LLC, H2 2016 28

Pipeline by Omeros Corporation, H2 2016 29

Pipeline by ProMetic Life Sciences Inc., H2 2016 30

Dormant Projects, H2 2016 47

Dormant Projects (Contd..1), H2 2016 48

Discontinued Products, H2 2016 49

List of Figures

List of Figures

Number of Products under Development for, H2 2016 8

Number of Products under Development by Therapy Area, H2 2016 9

Number of Products under Development by Top 10 Indication, H2 2016 10

Comparative Analysis by Late Stage Development, H2 2016 11

Comparative Analysis by Early Stage Products, H2 2016 12

Assessment by Monotherapy/Combination Products, H2 2016 15

Number of Products by Mechanism of Actions, H2 2016 16

Number of Products by Stage and Mechanism of Actions, H2 2016 16

Number of Products by Routes of Administration, H2 2016 18

Number of Products by Stage and Routes of Administration, H2 2016 18

Number of Products by Molecule Types, H2 2016 20

Number of Products by Stage and Molecule Type, H2 2016 20

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports